-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Coronary virus disease (COVID-19) in 2019 is a pandemic that has resulted in more than 25 million cases and 1 million deaths worldwide.
COVID-19 often leads to gastrointestinal diseases, including liver damage, however, it is not clear whether underlying liver disease affects the severity of COVID-19-related diseases.
liver fat degeneration (HS) and metabolic risk factors, including overweight, affect up to 30% of the population, obesity is associated with an increase in the severity of COVID-19 disease, and obesity is closely related to liver fatty degeneration (HS).
, however, how HS affects the severity of the disease in COVID-19, therefore, this study aims to explore the effects of HS on the severity of the disease and liver damage in COVID-19.
researchers conducted a single-center cohort study of hospitalized COVID-19 patients at Michigan Medical Center to study the association between HS and the severity of the disease.
HS is defined as a liver-fatty degeneration index of 36 (for Asians) or 39 (for non-Asians) and will be included in the study in patients with hepatic fatty degeneration more than 30 days before coVID-19 seizures.
the main observational outcomes were the severity of complications of cardiopulmonary disease, transaminase, jaundice and hypertension in the veins.
in 342 patients, metabolic diseases are common, including nearly 90 percent overweight.
HS is associated with an increase in transaminase, which requires intination, dialysis and boosters.
there is no association between HS and jaundice or valve hypertension complications.
in a sensitivity analysis, only patients with liver imaging more than 30 days before the onset of COVID-19 were included, and imaging evidence of liver fatty degeneration was still significantly associated with the severity of the disease and the elevation of transaminase.
, the researchers say HS is associated with an increase in the severity of the disease in COVID-19 and an increase in transaminase.
HS may be an effective indicator for predicting COVID-19-related complications.
.
